Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections.

× No keyword cloud information.

19 in total

Review 1. Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors: Ahmed H Badawi; Teruna J Siahaan
Journal: Clin Immunol Date: 2012-06-05 Impact factor: 3.969

2. Probing into the realm of proteins and immunity.

Authors: M Sela
Journal: Protein Sci Date: 1998-07 Impact factor: 6.725

Review 3. Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors: Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal: Arch Neurol Date: 2010-07-12

Review 4. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.

Authors: Ruth Arnon; Rina Aharoni
Journal: J Neural Transm (Vienna) Date: 2009-08-11 Impact factor: 3.575

Review 5. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors: Dene Simpson; Stuart Noble; Caroline Perry
Journal: CNS Drugs Date: 2002 Impact factor: 5.749

6. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.

Authors: Luc Van Kaer
Journal: Exp Neurol Date: 2010-10-20 Impact factor: 5.330

Review 7. Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.

Authors: Ruth Arnon; Rina Aharoni
Journal: Mol Neurobiol Date: 2007-10-11 Impact factor: 5.590

8. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

Authors: Kenneth P Johnson
Journal: Ther Clin Risk Manag Date: 2010-04-15 Impact factor: 2.423

9. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

Authors: Ruth Arnon; Rina Aharoni
Journal: Proc Natl Acad Sci U S A Date: 2004-09-15 Impact factor: 11.205

Review 10. Interferon beta and glatiramer acetate therapy.

Authors: Corey A McGraw; Fred D Lublin
Journal: Neurotherapeutics Date: 2013-01 Impact factor: 7.620